Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06037252 · ClinicalTrials.gov registry record · Phase 2
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
A Phase 2 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 414
- Enrollment target
- 20
- Study locations
NCT06037252: Active Phase 2 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.
NCT06037252 is a Phase 2 study of Obesity and Type 2 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 414 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06037252, a Phase 2 study of Obesity and Type 2 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 414 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
California
- John Muir Physician Network Research Center - Concord
- Care Access - Sacramento - Sacramento
Florida
- Retreat Medical Research - Miami
- American Research Centers of Florida - Pembroke Pines
Georgia
- Alta Pharmaceutical Research Center - Norcross
- AGILE Clinical Research Trials, LLC - Sandy Springs
Texas
- Juno Research - Houston
- Southern Endocrinology Associates - Mesquite
Arizona
- Medical Advancement Centers of Arizona - Phoenix
Colorado
- Care Access - Aurora - Aurora
Connecticut
- Chase Medical Research, LLC - Waterbury
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What the registry record for NCT06037252 still lists
NCT06037252 is an interventional study that assigns participants to a tested intervention. The registered 414 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (49% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06037252 names 20 study sites across 16 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06037252 about?
NCT06037252 is a clinical study titled "A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity". The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
What is the current status of trial NCT06037252?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 414 participants. The study started on 2023-09-21. Estimated completion is 2026-10.
What conditions does trial NCT06037252 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes.
What interventions are being tested in trial NCT06037252?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06037252?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06037252 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06037252's enrollment target sits among peer trials
414 163rd of 1053 higher than 891 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04776941 · 414 participants · NA
Expressive Writing for the Management of Stress in Cancer Survivors
- NCT06792552 · 414 participants · Phase 1
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- NCT05142605 · 415 participants · NA
Evaluation of Grief Therapy Approaches for Bereaved Parents
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI